InvestorsHub Logo
Followers 511
Posts 59403
Boards Moderated 4
Alias Born 12/21/2009

Re: 21money21 post# 98

Monday, 03/27/2017 10:23:58 AM

Monday, March 27, 2017 10:23:58 AM

Post# of 459
Wedbush Securities analyst Liana Moussatos lowered its price target on Regulus Therapeutics (NASDAQ: RGLS) to $6.00 (from $8.00) while maintaining a Outperform rating, noting the company's early proof-of mechanism for RG-012 for Rare Alport Syndrome could be achieved before year-end, as cash balance provides runway through clinical catalysts.

https://www.streetinsider.com/Analyst+Comments/Regulus+Therapeutics+(RGLS)+PT+Lowered+to+%246+at+Wedbush+Following+Adjustment+to+Launch+Timing+for+RG-012/12632267.html

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RGLS News